At the news
? BEARISHIMPACT 7/10 8-K filed Aug 10, 2026 at 16:12 ET
TELA Bio reported Q2 2026 revenue of $19.3M, a 4% decline YoY, and an EPS of -$0.20, missing consensus estimates of -$0.18. The company withdrew its full-year 2026 revenue guidance, citing a decline in OviTex PRS volumes and ongoing price/mix headwinds. A new CEO was appointed, but the guidance withdrawal and revenue miss signal significant near-term uncertainty and deteriorating fundamentals for this $39M market-cap medical device company.
- Revenue declined 4% YoY to $19.3M, missing consensus of $20.0M
- EPS of -$0.20 missed consensus of -$0.18 (-12.4% miss)
- Full-year 2026 revenue guidance withdrawn, citing OviTex PRS volume decline and competitive bundling pressures
- Net loss widened to $11.3M from $9.9M in the prior-year quarter
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access